Brigatinib Outperforms Crizotinib as First-Line Therapy.

The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in patients with untreated non-small cell lung cancer. Brigatinib yielded a longer progression-free survival, a higher objective response rate, and greater effectiveness against brain metastases-and was less detrimental to patients' quality of life. ©2019 American Association for Cancer Research.